The Demand
The pill that wasn't: why there is no oral Melanotan II
The gray market has begun selling Melanotan II in forms the needle era never had: capsules, gummies, flavored drinks. They are the friendliest costume yet. They are also, as a delivery of this molecule, a chemical impossibility.
Melanotan II is a cyclic peptide — seven amino acids locked into a ring. That ring was engineered in the 1980s precisely so the molecule could survive long enough, once injected, to outlast the body’s own α-MSH, which is destroyed within minutes. The digestive tract is a different problem from plasma enzymes. A swallowed peptide meets stomach acid and a battery of proteases whose entire job is dismantling proteins into single amino acids before they cross the gut wall. Cyclicity slows the process. It does not stop it, and nothing about this molecule crosses the gut wall intact in meaningful quantities.
Every approved melanocortin drug confirms the point by example. Afamelanotide is a subcutaneous implant. Bremelanotide is an auto-injector. Setmelanotide is a daily injection. Three companies, holding the patents, with every commercial incentive to sell a pill, sell needles. The wellness-menu vendors selling a capsule have no patent, no lab, and no incentive to tell you why.
What an oral product actually is
That leaves two possibilities, and neither is an oral tanning peptide.
The product contains no Melanotan II at all. Any colour change it produces comes from something else — and the history of that something else has its own ending. Canthaxanthin “tanning pills” were sold for decades before the FDA made its position plain: the colour additive is approved for food, not for tanning, and the pills have been linked to canthaxanthin retinopathy — crystals in the eye — and liver problems. Dyes colour the skin from the inside. They are not a tan, and they are not melanin.
Or the product does contain Melanotan II — in which case it is paying for a molecule that will be digested before it can reach a single receptor, and whatever effect the buyer notices is not the peptide.
The vial problem applies at both exits. A capsule from an unknown vendor is an assumption inside a gelatin shell: no pharmacopeia, no label verification, no regulator who has ever seen the batch.
The market sells the pill because the pill is what a nervous buyer wants to exist — the tan without the needle, the needle without the decision. The chemistry doesn’t care what the buyer wants. An oral Melanotan product that appears to work is the proof that it isn’t one.